NRG
REGN icon

Nemes Rush Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Nemes Rush Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99K Hold
8
– – ﹤0.01% 666
2026
Q1 		$6.18K Hold
8
– – ﹤0.01% 611
2025
Q4 		$6.17K Buy
+8
New +$5.43K ﹤0.01% 599

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Nemes Rush Group's REGN Position: Q2 2026 in Review

Nemes Rush Group held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 8 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Nemes Rush Group first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.18K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Nemes Rush Group held 8 shares of Regeneron Pharmaceuticals worth $4.99K as of Q2 2026.
  • Nemes Rush Group left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #666 holding.
  • Nemes Rush Group first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nemes Rush Group's Regeneron Pharmaceuticals position peaked at $6.18K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.